绿脓杆菌感染,尤其当该菌耐氨基糖苷类抗生素时是难治的;而广泛用以治疗绿脓杆菌感染的羧苄青霉素及羧噻吩青霉素(Ticarcillin)对该菌仅具中等抗菌活性。本文讨论近年来发展的具有较强抗绿脓杆菌活性的β-内酰胺类抗生素,其中包括新的头孢菌素类、青霉素类、恶唑β-内酰胺类、硫霉素(Thienamycin)及诺卡菌素A(Nocardicin A)。对这些药物的评价要考虑到多种因素。β-内酰胺类抗生素的抗绿脓杆菌活性决定于其穿透细胞壁的能力和在细胞膜上与青霉素结合蛋白的亲和力,同样重要的是它对β-内酰胺酶的稳定性;并须结 Pseudomonas aeruginosa infection, especially when the bacteria resistant to aminoglycoside antibiotics is refractory; and widely used to treat Pseudomonas aeruginosa infections carbenicillin and carbaryl thiophene penicillin (Ticarcillin) only moderate antibacterial activity against the bacteria. This article discusses beta-lactam antibiotics that have been developed in recent years with strong resistance to Pseudomonas aeruginosa, including new cephalosporins, penicillins, oxazole beta-lactams, thienamycin, Nocardicin A. The evaluation of these drugs to take into account many factors. The anti-Pseudomonas aeruginosa activity of [beta] -lactam antibiotics depends on their ability to penetrate the cell wall and their affinity for penicillin-binding proteins on the cell membrane, and equally important is its stability to [beta] -lactamase;